Abooali, Maryam, Lei, Xi, Yasinska, Inna M., Schlichtner, Stephanie, Hussain, Rohanah, Siligardi, Giuliano, Gianga, Tiberiu-Marius, Berger, Steffen M., Cholewa, Dietmar, Gibbs, Bernhard F., and others. (2025) Ligand-receptor interactions of V-domain Ig-containing suppressor of T cell activation and programmed death-1 suppress the anticancer activities of T cells. Immuno-oncology and Technology, 28 . Article Number 101533. ISSN 2590-0188. (doi:10.1016/j.iotech.2025.101533) (KAR id:115335)
|
PDF
Publisher pdf
Language: English
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
|
Download this file (PDF/2MB) |
Preview |
| Request a format suitable for use with assistive technology e.g. a screenreader | |
| Official URL: https://doi.org/10.1016/j.iotech.2025.101533 |
|
Abstract
Background: V-domain immunoglobulin-containing suppressor of T cell activation (VISTA) is a unique multifunctional immune checkpoint protein, which can display both receptor and ligand properties. It plays a crucial role in the cancer immune evasion machinery operated by a wide range of human malignancies and may thus be considered as a potential target for immunotherapy of cancer. Receptors of VISTA through which this protein transmits immunosuppressive signals under various normal and pathological conditions remain to be identified.
Materials and methods: To conduct the study, we used human recombinant proteins and various human cell lines as well as primary T cells. A wide range of techniques including tissue culture and co-cultures, Western blot analysis, on-cell Western, ELISA, co-immunoprecipitation, biochemical assays and synchrotron radiation circular dichroism spectroscopy were employed.
Results: Here we report for the first time that VISTA has affinity to programmed cell death protein 1 (PD-1) and binds it as a ligand. We found that when interacting with PD-1, VISTA suppresses interleukin 2 production by T helper cells. These effects were confirmed in the in vitro and ex vivo experiments. Affinity of VISTA to PD-1 was also characterised and found to be moderate, with a Kd of ∼2.3 μM detected by synchrotron radiation circular dichroism spectroscopy.
Conclusions: These results open a completely new chapter in our understanding of the concept of immune checkpoint proteins, where some of them clearly show both ligand and receptor activities and display multifunctional properties.
| Item Type: | Article |
|---|---|
| DOI/Identification number: | 10.1016/j.iotech.2025.101533 |
| Subjects: | R Medicine > RM Therapeutics. Pharmacology |
| Institutional Unit: | Schools > Medway School of Pharmacy |
| Former Institutional Unit: |
There are no former institutional units.
|
| Funders: | Diamond Light Source (https://ror.org/05etxs293) |
| Depositing User: | Vadim Sumbayev |
| Date Deposited: | 17 May 2026 16:44 UTC |
| Last Modified: | 01 Jul 2026 11:35 UTC |
| Resource URI: | https://kar.kent.ac.uk/id/eprint/115335 (The current URI for this page, for reference purposes) |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):

https://orcid.org/0000-0002-8743-7795
Altmetric
Altmetric